First Turn Management LLC Invests $13.20 Million in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN)

First Turn Management LLC bought a new position in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN - Free Report) in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm bought 947,878 shares of the company's stock, valued at approximately $13,204,000. Day One Biopharmaceuticals makes up about 2.1% of First Turn Management LLC's portfolio, making the stock its 28th biggest position. First Turn Management LLC owned 0.94% of Day One Biopharmaceuticals as of its most recent SEC filing.

A number of other institutional investors have also made changes to their positions in the company. Mirae Asset Global Investments Co. Ltd. boosted its holdings in Day One Biopharmaceuticals by 38.4% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,611 shares of the company's stock worth $51,000 after purchasing an additional 1,002 shares during the period. Quest Partners LLC boosted its holdings in shares of Day One Biopharmaceuticals by 9,238.6% in the 3rd quarter. Quest Partners LLC now owns 7,751 shares of the company's stock valued at $108,000 after buying an additional 7,668 shares during the period. SG Americas Securities LLC acquired a new stake in Day One Biopharmaceuticals during the second quarter worth about $113,000. Point72 DIFC Ltd acquired a new stake in Day One Biopharmaceuticals during the second quarter worth about $124,000. Finally, Hsbc Holdings PLC acquired a new position in Day One Biopharmaceuticals in the second quarter valued at approximately $163,000. 87.95% of the stock is currently owned by institutional investors.

Day One Biopharmaceuticals Stock Up 3.9 %

Shares of DAWN stock traded up $0.51 during mid-day trading on Tuesday, hitting $13.52. 819,366 shares of the stock traded hands, compared to its average volume of 960,703. Day One Biopharmaceuticals, Inc. has a twelve month low of $11.30 and a twelve month high of $18.07. The company's 50-day simple moving average is $14.40 and its 200-day simple moving average is $14.31.

Day One Biopharmaceuticals (NASDAQ:DAWN - Get Free Report) last released its earnings results on Wednesday, October 30th. The company reported $0.38 EPS for the quarter, topping analysts' consensus estimates of ($0.20) by $0.58. The business had revenue of $93.76 million during the quarter, compared to the consensus estimate of $15.05 million. During the same quarter in the previous year, the firm earned ($0.54) earnings per share. Equities analysts expect that Day One Biopharmaceuticals, Inc. will post -0.88 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

DAWN has been the topic of several recent research reports. Bank of America raised Day One Biopharmaceuticals from an "underperform" rating to a "buy" rating and raised their price target for the stock from $11.00 to $24.00 in a report on Thursday, August 1st. JPMorgan Chase & Co. lowered their price target on shares of Day One Biopharmaceuticals from $38.00 to $36.00 and set an "overweight" rating for the company in a research report on Tuesday, August 6th. HC Wainwright reaffirmed a "buy" rating and issued a $40.00 price objective on shares of Day One Biopharmaceuticals in a report on Thursday, October 31st. Needham & Company LLC reissued a "buy" rating and set a $33.00 target price on shares of Day One Biopharmaceuticals in a research note on Thursday, October 31st. Finally, Wedbush restated an "outperform" rating and issued a $33.00 target price on shares of Day One Biopharmaceuticals in a research report on Thursday, July 25th. One research analyst has rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat, Day One Biopharmaceuticals currently has an average rating of "Buy" and a consensus price target of $35.71.

Insider Transactions at Day One Biopharmaceuticals

In other Day One Biopharmaceuticals news, insider Samuel C. Blackman sold 30,000 shares of the company's stock in a transaction dated Tuesday, September 10th. The shares were sold at an average price of $14.22, for a total transaction of $426,600.00. Following the completion of the sale, the insider now directly owns 1,097,535 shares of the company's stock, valued at approximately $15,606,947.70. This represents a 2.66 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders sold a total of 51,745 shares of company stock valued at $775,867 in the last three months. 8.40% of the stock is currently owned by corporate insiders.

About Day One Biopharmaceuticals

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.